Valuation: NanoVibronix Inc

Market Cap 3.63M 3.14M 2.93M 2.69M 5.08M 345M 5.14M 34.4M 13.5M 172M 13.62M 13.32M 571M P/E 2024
-0.47x
P/E 2025 -0.09x
Enterprise Value 599K 519K 483K 445K 839K 56.93M 849K 5.68M 2.23M 28.48M 2.25M 2.2M 94.34M EV / Sales 2024
0.62x
EV / Sales 2025 -0.2x
Free-Float
79.08%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 57 2025-06-03
Director of Finance/CFO 53 2025-12-17
Chief Tech/Sci/R&D Officer 45 2024-05-31
Director TitleAgeSince
Director/Board Member 57 2025-02-13
Chairman 76 2026-07-13
Director/Board Member 48 2025-12-04
Change 5-day change 1-year change 3-year change Capi.($)
+5.56%-35.71% - - 3.44M
-1.30%+1.76%-13.98%-16.57% 13.9B
+3.87%+4.54%+48.77%-2.62% 4.02B
-0.82%+7.28%-36.64%-52.60% 1.31B
-3.13%+11.14%-33.69%-40.07% 1.27B
-1.36%-2.55%+32.04%+89.71% 1.19B
-1.11%+5.65%-46.01% - 972M
+14.85%+15.58%+30.97%+126.54% 472M
-2.45%+2.11%+63.53% - 347M
-0.55%+2.17%-61.28%+227.45% 258M
Average +1.36%+5.97%-1.81%+47.41% 2.64B
Weighted average by Cap. -0.18%+1.45%-3.13%-6.03%

Financials

2024 2025
Net sales 2.56M 2.22M 2.07M 1.9M 3.59M 243M 3.63M 24.27M 9.53M 122M 9.61M 9.4M 403M 2.55M 2.21M 2.06M 1.9M 3.58M 243M 3.62M 24.22M 9.51M 121M 9.59M 9.38M 402M
Net income -3.7M -3.21M -2.99M -2.75M -5.19M -352M -5.25M -35.15M -13.8M -176M -13.92M -13.61M -584M -18.18M -15.75M -14.68M -13.5M -25.49M -1.73B -25.78M -173M -67.72M -865M -68.3M -66.79M -2.87B
Net Debt -636K -551K -513K -472K -892K -60.48M -902K -6.03M -2.37M -30.26M -2.39M -2.34M -100M -3.03M -2.62M -2.44M -2.25M -4.24M -288M -4.29M -28.72M -11.27M -144M -11.37M -11.12M -477M
Logo NanoVibronix Inc
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
Employees
-